MiMedx Group, Inc. is a healthcare company providing advanced wound care, burn, and surgical solutions. The company focuses on placental allografts derived from human birth tissue, processed through its proprietary PURION process, and has expanded its portfolio to include animal-derived xenografts and synthetic wound care modalities. Key products include EPIFIX, CELERA, EMERGE, and HELIOGEN Fibrillar Collagen Matrix. In 2025 and early 2026, the company entered exclusive distribution agreements for RegenKit-Wound Gel, NovaForm Wound Matrix, G4Derm Plus, and Hydrelix Collagen Matrix. MiMedx serves clinicians in the United States, with primary applications in surgical settings, wound care centers, and hospital environments for treating chronic and hard-to-heal wounds such as diabetic foot ulcers and venous leg ulcers. The company is pursuing international expansion, primarily targeting Japan. Products are regulated by the U.S. Food and Drug Administration (FDA) and other international regulatory agencies.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage mimedx.com
Sector Healthcare IR page investors.mimedx.com
Tags
wound care, placental allografts, xenografts, skin substitutes, burn care, surgical applications, chronic wounds, tissue engineering, EPIFIX, CELERA, EMERGE, HELIOGEN, RegenKit-Wound Gel, NovaForm Wound Matrix, G4Derm Plus, Hydrelix Collagen Matrix, PURION
Press page —

Metrics

Valuation  
Market cap $ 680.013M
Market cap (USD) $ 680.013M
P/E -35.85
PEG —
P/BV 3.22
P/S 2.24
P/OCF 32.79
P/FCF 9.32
Dividend yield —
Turnover / mcap —
Returns  
ROE 21.6%
ROI 17.7%
ROIC 17.1%
Profit margin 11.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 8.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 1
Quality score 23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2008 FY 2007
Revenue 418.63M 348.879M 321.477M 267.841M 258.615M 248.234M 299.255M 359.111M 321.139M 245.015M 187.296M 118.223M 59.181M 27.054M 7.76M 788.874K — —
Net profit 48.578M 42.419M 58.228M -30.197M -10.285M -49.284M -25.58M -29.979M 64.727M 11.974M 29.446M 6.22M -4.112M -7.662M -10.194M -11.42M — —
Free cash flow 72.97M 64.515M 24.788M -19.407M -5.2M — — — — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2008 FY 2007
Share price 6.77 9.62 8.77 2.78 6.04 9.08 7.58 1.79 12.61 8.86 9.37 11.53 8.74 3.52 0.98 0.99 — —
Price performance 12m -0.3 0.1 2.15 -0.54 -0.33 0.2 3.23 -0.86 0.42 -0.05 -0.19 0.32 1.48 2.59 -0.01 — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 67.2M — 0.00 32.3M 35.4M 40.4M 43.1M 53.9M 55.8M 75.7M
↳ YoY growth +24.9% +9.6% +13.9% +6.8% +25.0% +3.6% +35.6%
↳ 5y CAGR +104.2% +3.9% -8.0% -9.7% +11.5% +16.4%
Borrowings, current (USD) — — 0.00 3.75M 0.00 — — 1M 1M 1.5M
Borrowings, non-current (USD) — — 0.00 61.9M 47.7M 48.1M 48.6M 48.1M 17.8M 16.5M
Lease liabilities (USD) — — — 4.09M 4.14M 5.17M 3.88M 2.45M 6.01M 4.57M
Cash and deposits (USD) 34.4M 27.5M 45.1M 69.1M 95.8M 87.1M 66M 82M 104M 166M
Intangible assets (USD) 23.3M 10M 9.61M 7.78M 6M 5.38M 5.85M 5.26M 11.6M 14.2M
Right-of-use assets (USD) — — 0.00 3.4M 3.62M 4.7M 3.4M 2.13M 5.61M 4.34M
Net debt (borrowings + leases - cash) (USD) — — -45.1M -3.44M -44M -33.8M -13.5M -31.5M -79.6M -144M
Cash flow detail
Operating cash flow (USD) 25.8M 62.9M 35.8M -39.4M -30.3M -1.98M -17.9M 26.8M 66.2M 74M
Purchases of property, plant and equipment (USD) — — — — — -3.22M -1.51M -1.99M — —
Purchases of intangible assets (USD) — — -600,000 -500,000 -327,000 -252,000 -1M 0.00 0.00 —
Change in receivables (cash effect) (USD) -11.4M -479,000 0.00 -10.9M -3.1M -4.93M -5.55M -12.2M -2.55M -26.4M
Change in inventories (cash effect) (USD) -2.84M 2.75M -6.52M 6.88M -1.26M -1.03M -1.79M -7.84M -2.36M -1.53M
Change in payables (cash effect) (USD) -3.67M -1.32M 6.59M -6.17M 177,000 -326,000 1.05M 783,000 -1.41M 2.12M
Share buybacks (cash effect) (USD) -10.3M -68.3M -7.6M — -900,000 0.00 0.00 -9.52M 0.00 0.00
Interest paid (cash effect) (USD) -162,000 -127,000 -197,000 -4.33M -7.46M -4.33M -4.57M -6.03M -2.7M -1.25M
Income taxes paid (cash effect) (USD) -642,000 -12.8M -859,000 -308,000 -208,000 -169,000 -181,000 548,000 -3.25M -8.51M
Share-based compensation (USD) 17.8M 21.2M 14.8M 12.1M 15.4M 14.8M 12.7M 17M 16.9M 16.4M
Operating cash flow before change in receivables (USD) 37.2M 63.4M 35.8M -28.5M -27.2M 2.95M -12.3M 39M 68.8M 100M
Free cash flow (OCF - PPE - intangibles) (USD) — — — — — -5.2M -20.4M 24.8M — —
Income detail
Research and development expense (USD) 12M 17.9M 15.8M 11.1M 11.7M 17.3M 22.8M 12.7M 12.3M 15.1M
↳ 5y CAGR +35.8% +44.1% +26.6% +9.6% +6.8% +7.6% +5.0% -4.3% +2.1% +5.2%
Provision for credit losses (USD) — — — — 0.00 0.00 2.82M 1.45M 595,000 6.52M
Credit cost ratio (credit losses / average receivables) (%) — — — — 0.0% 0.0% 6.8% 3.0% 1.1% 9.9%
Reported Mar 1, 2017 Mar 17, 2020 Mar 8, 2021 Mar 8, 2021 Feb 28, 2023 Feb 28, 2024 Feb 28, 2024 Apr 30, 2024 Feb 26, 2025 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 6, 2026

PDF Version

MARIETTA, Ga., Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:

Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New York, NY Wednesday, November 11, 2026 1:1 sessions + presentation (9:00 am EST): webcast

Craig-Hallum 17thAnnual Alpha Select Conference | New York, NY Tuesday, November 17, 2026 1:1 sessions

Investors interested in meeting with senior management at these events may contact their respective Canaccord or Craig-Hallum representative.

About MIMEDX MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

On October 28, 2026, MiMedx Group, Inc. (the “Company”), issued a press release (the “Earnings Press Release”) announcing its results for the second quarter of 2026. A copy of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

It may only be incorporated by reference into another filing under the Exchange Act or Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references this Form 8-K. All information in the Earnings Press Release speaks as of the date thereof and the Company does not assume any obligation to update such information in the future. In addition, the Company disclaims any inference regarding the materiality of such information which otherwise may arise as a result of its furnishing such information under Item 2.02 of this report on Form 8-K.

Regulation FD

On October 28, 2026 at 4:30 PM Eastern Daylight Time, the Company intends to host a conference call and webcast (the “Earnings Call”) to discuss its financial and operating results for the third quarter of 2026.

MIMEDX Announces $25 Million Patent License Agreement Bull 3 Bear 0 Order/contract

October 28, 2026

PDF Version

MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into a license agreement with a wound care competitor that resolves allegations of infringement of MIMEDX’s patents.

Under the terms of the agreement:

  • The licensee will pay MIMEDX a total of $25 million in five equal installments of $5 million.

  • The first installment has been received, and the four remaining installments will be paid annually on the anniversary of the signing date.

  • MIMEDX has granted the licensee a non-exclusive license to the covered patents.

“This agreement underscores the strength and value of the intellectual property portfolio MIMEDX has built since its inception. We believe our expertise in placental biologics is unmatched, and this agreement recognizes the innovation behind our product portfolio and pipeline. It also provides MIMEDX with meaningful, recurring cash over the next several years. We will continue to vigorously protect our intellectual property while investing in further innovation and differentiation in the marketplace,” said Joseph H. Capper, Chief Executive Officer of MIMEDX.

The counterparty to this agreement is not involved in either of MIMEDX’s two ongoing patent infringement actions, in both of which MIMEDX has secured favorable claim construction rulings. The Company also recently received a favorable reexamination decision from the U.S. Patent and Trademark Office confirming the validity of all sixteen claims of its ’092 patent without amendment.

About MIMEDX MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Prompts

MiMedx Group, Inc (ticker MDXG), listed in United States.

Company History

Date Change Detail
Apr 4, 2008 Renamed Alynx, Co. → MIMEDX GROUP, INC.

ETFs Holding MiMedx Group, Inc

ETF Weight in ETF Shares Market value As of
SQLV 0.20% 14,720 $ 56.672K Jun 30, 2026
FSML 0.09% 30,421 $ 117.121K Jun 30, 2026
FSEG 0.07% 1,076 $ 4,142.60 Jun 30, 2026
IVSS 0.05% 3,810 $ 14.669K Jun 30, 2026
VFQY 0.05% 60,480 $ 274.579K Aug 31, 2026
AVUV 0.03% 2,611,084 $ 8.303M Nov 16, 2026
PSC 0.03% 154,971 $ 596.638K Jun 30, 2026
AVSC 0.02% 214,982 $ 683.643K Nov 16, 2026
RESM 0.01% 138 $ 531.30 Jun 30, 2026
DFAS 0.01% 712,443 $ 2.308M Nov 12, 2026
DFAT 0.01% 617,247 $ 2M Nov 12, 2026
AVUS 0.00% 68,075 $ 216.479K Nov 16, 2026
AVSU 0.00% 816 $ 2,594.88 Nov 16, 2026